Elicio Therapeutics (ELTX) EBITDA (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly EBITDA came in at -$10.6 million in Q1 2026, up 1.25% YoY from -$10.5 million in Q1 2025, and down 19.9% on a QoQ basis from -$8.8 million in Q4 2025.
Elicio Therapeutics (ELTX) EBITDA (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of EBITDA data on file, last reported at -$10.6 million in Q1 2026.
- Quarterly EBITDA rose 1.25% year-over-year to -$10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.6 million (up 17.37% YoY) and the FY2025 annual result came in at -$37.7 million, up 16.17% from the prior year.
- EBITDA retreated to -$10.6 million in Q1 2026, from -$8.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$5.8 million in Q3 2022 to a low of -$14.5 million in Q1 2022.
- A 5-year average of -$9.5 million and a median of -$10.1 million in 2025 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 65.84% in 2022, down 140.73% in 2022.
- Tracing ELTX's EBITDA over 5 years: stood at -$6.0 million in 2022, then sank by 57.56% to -$9.4 million in 2023, then sank by 43.48% to -$13.5 million in 2024, then surged by 34.39% to -$8.8 million in 2025, then decreased by 19.9% to -$10.6 million in 2026.
- The last three EBITDA figures came in at -$10.6 million (Q1 2026), -$8.8 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | -10.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.43 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Dec 31, 2025 | -8.84 Mn |
| Sep 30, 2025 | -8.05 Mn |
| Jun 30, 2025 | -10.09 Mn |
| Mar 31, 2025 | -10.74 Mn |
| Dec 31, 2024 | -13.48 Mn |
| Sep 30, 2024 | -10.34 Mn |
| Jun 30, 2024 | -10.92 Mn |
| Mar 31, 2024 | -10.24 Mn |
| Dec 31, 2023 | -9.39 Mn |
| Sep 30, 2023 | -10.77 Mn |
| Jun 30, 2023 | -7.78 Mn |
| Mar 31, 2023 | -7.81 Mn |
| Dec 31, 2022 | -5.96 Mn |
| Sep 30, 2022 | -5.77 Mn |
| Jun 30, 2022 | -6.23 Mn |
| Mar 31, 2022 | -14.49 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | -15.76 Mn |